Life Sciences & Biotech IP Search

Life Sciences — Where Patents Mean Billions

No sector produces patent assets of higher individual commercial value than pharmaceuticals and biotechnology. A single composition-of-matter patent claiming the chemical structure of an active pharmaceutical ingredient can generate revenues in the hundreds of billions over its lifecycle. Patent litigation and validity challenges are fought with an intensity unmatched anywhere in IP law.

Small Molecule Drug IP — The Hatch-Waxman Framework

Pharmaceutical patent protection involves three overlapping layers. Composition-of-matter patents claim the API chemical structure itself — the broadest protection, expiring 20 years from filing. Process patents cover synthesis routes and can remain relevant to generics even after composition patents expire, if the generic uses the same synthetic pathway. Formulation patents cover drug products — crystalline polymorphs, controlled-release delivery systems, tablet compositions, drug-device combinations.

The US Hatch-Waxman framework allows generic manufacturers to file abbreviated new drug applications (ANDAs) citing the originator's clinical data, and requires the generic to certify against listed patents. Paragraph IV certifications — asserting patents are invalid or not infringed — trigger automatic 30-month stays and subsequent patent litigation. The invalidity searches supporting paragraph IV litigation are among the most technically demanding in pharmaceutical IP, requiring deep organic chemistry knowledge to identify prior art in chemical synthesis literature spanning over a century.

mRNA Therapeutics — The Post-COVID IP Landscape

The COVID-19 pandemic demonstrated mRNA therapeutics at scale and triggered an explosion of patent filing in: nucleoside modification chemistry (N1-methylpseudouridine modification enabling mRNA stability — the Katalin Karikó and Drew Weissman discovery), lipid nanoparticle (LNP) delivery systems (the ionisable lipid enabling endosomal escape — ALC-0315 in Pfizer/BioNTech's vaccine, SM-102 in Moderna's), mRNA sequence optimisation (UTR elements, codon optimisation algorithms), and manufacturing process (in vitro transcription, cap analogue incorporation, purification).

The Moderna vs BioNTech/Pfizer mRNA patent dispute involves foundational patents on pseudouridine nucleoside modification. Acuitas Therapeutics, Arbutus Biopharma, and Alnylam Pharmaceuticals hold foundational LNP delivery patents that cover not just COVID vaccines but the entire future of mRNA therapeutics — with billions in royalties at stake across oncology, rare diseases, and infectious disease prevention programmes.

CRISPR Gene Editing — The Most Contested IP in History

CRISPR-Cas9 gene editing — enabling precise, programmable DNA cuts via a guide RNA directing the Cas9 nuclease — generated a patent interference proceeding between the Broad Institute (Harvard/MIT, led by Feng Zhang) and the University of California Berkeley (Jennifer Doudna lab) that became the most followed IP dispute in biotechnology. The Broad Institute's claims to CRISPR application in eukaryotic (human) cells were upheld through multiple rounds of USPTO Patent Trial and Appeal Board (PTAB) proceedings and Federal Circuit appeal.

The commercial licensing structure is consequential: Broad licenses to Editas Medicine exclusively; Berkeley licenses to CRISPR Therapeutics and Intellia Therapeutics. Next-generation editing tools — base editors (Beam Therapeutics, David Liu's lab at Broad), prime editors (Prime Medicine, Liu lab), epigenome editors — are creating new patent waves as the technology advances. Each editing modality has its own IP landscape that overlaps with but is distinct from the foundational CRISPR-Cas9 disputes.

CAR-T Cell Therapy IP

Chimeric Antigen Receptor T-cell therapy engineers a patient's immune cells to attack cancer. The patent landscape covers CAR construct architecture (costimulatory domains — CD28 vs 4-1BB, scFv targeting sequences, transmembrane anchoring domains), T-cell manufacturing (lentiviral vs retroviral transduction, CRISPR-based gene editing for allogeneic off-the-shelf CAR-T), clinical protocols, and tumour microenvironment interaction. Juno Therapeutics (acquired by Bristol Myers Squibb for $9B) and Kite Pharma (acquired by Gilead for $11.9B) fought landmark litigation over CD28 costimulatory domain patents — ultimately settled — shaping the commercial structure of the entire CAR-T industry.

Biologics and the Biosimilar Challenge

Biologic drugs — monoclonal antibodies, fusion proteins, recombinant hormones — are produced in living cell systems rather than chemical synthesis. Biosimilar manufacturers attempting to enter markets after originator biologic patents expire face the 12-year US data exclusivity period, dense secondary patent thickets (process patents, formulation patents, manufacturing patents filed after the originator's composition patent), and the regulatory complexity of demonstrating biosimilarity through extensive analytical and clinical studies. Invalidity searches for biosimilar programmes require understanding cell culture process patents, protein purification (Protein A chromatography, virus filtration), formulation stability, and device patents covering autoinjectors and prefilled syringes.